Niveau de preuve pour le suivi thérapeutique pharmacologique de la vancomycine

Jelassi, M.; Benlmouden, A.; Lefeuvre, Sandrine; Mainardi, Jean–Luc; Billaud, Éliane

doi:10.2515/therapie/2011005

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2012

2024

Publication Types

Select...

Article5

Book1

Relationship

Self Cite0

Independent6

Authors

Journals

Cited by 8 publications

(1 citation statement)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have analyzed the continuous i.v. infusion method, which is increasingly used to obtain a higher vancomycin serum level and steadier target concentration (11)(12)(13) compared to the conventional method, i.e., intermittent infusion. However, no improved drug activity and no change in the course of the disease has been demonstrated with either method (14,15).…”

mentioning

confidence: 99%

Influence of Vancomycin Infusion Methods on Endothelial Cell Toxicity

Drouet

Chai

Barthélémy

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

mentioning

confidence: 99%

Influence of Vancomycin Infusion Methods on Endothelial Cell Toxicity

Drouet

Chai

Barthélémy

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review

Elyasi

Khalili

Dashti‐Khavidaki

et al. 2012

Eur J Clin Pharmacol

365

296

View full text Add to dashboard Cite

Vancomycin-induced renal toxicity was reported in 10-20 % and 30-40 % of patients following conventional and high doses of vancomycin therapy, respectively .The most probable mechanism for its nephrotoxicity can be at least partially attributable to an increased production of reactive oxygen species and oxidative stress. There are a number of different risk factors which could accelerate or potentiate the occurrence of vancomycin-induced nephrotoxicity, with the most documented risk factors being high trough vancomycin level (especially >20 mg/L) or doses (>4 g/day), concomitant treatment with nephrotoxic agents, prolonged therapy (even more than 7 days), and admittance to an intensive care unit (especially prolonged stay). It is necessary to carry out more studies, especially those focused on the association between nephrotoxicity and high trough levels of vancomycin.

show abstract